# US 2020/0390878 A1 · Recombinant swinepox virus and vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390878 A1
- Document ID: US20200390878A1
- Status: Published application
- Kind: A1
- Application number: 16/770,636
- Filed: 2018-12-07
- Published: 2020-12-17
- Earliest claimed: 2017-12-08
- Applicants: Ceva Sante Animale
- Inventors: DOLORES RODRIGUEZ AGUIRRE; MATEO DEL POZO VEGAS; JOSE FRANCISCO RODRIGUEZ AGUIRRE; JUAN RAMON RODRIGUEZ FERNANDER-ALBA
- Web page: https://patentgrep.com/patent/US20200390878A1

## CPC

- A61K 39/12: Viral antigens
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention contain an inactive serpin gene and may be used to express any nucleic acid of interest.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A recombinant swinepox virus (rSPV) comprising an inactive serpin gene.

### Claim 20 (depends on 19)

The rSPV of claim 19, further comprising an inactive thymidine kinase (TK) gene and/or an inactive IL18bp gene.

### Claim 21 (depends on 19)

The rSPV of claim 19, comprising an inactive serpin gene, an inactive thymidine kinase (TK) gene, and an inactive IL18bp gene.

### Claim 22 (depends on 19)

The rSPV of claim 19, wherein the rSPV genome comprises a deletion of at least 50 bp or at least 100 bp in the coding sequence of each inactive gene.

### Claim 23 (depends on 19)

The rSPV of claim 19, said rSPV comprising at least one foreign nucleic acid sequence.

### Claim 24 (depends on 23)

The rSPV of claim 23, wherein the foreign nucleic acid sequence is inserted in a region of the rSPV genome selected from the IL18bp gene, the TK gene, the serpin gene, or the Ankyrin repeat protein gene.

### Claim 25 (depends on 23)

The rSPV of claim 23, wherein the at least one foreign nucleic acid sequence encodes an antigen.

### Claim 26 (depends on 25)

The rSPV of claim 25, wherein the foreign nucleic acid sequence encodes a porcine circovirus (PCV) antigen, a PCV2 antigen, a PCV2 capsid antigen, or a PCV2 ORF2 protein or peptide.

### Claim 27 (depends on 23)

The rSPV of claim 23, wherein the foreign nucleic acid sequence contains a transcriptional promoter.

### Claim 28 (depends on 27)

The rSPV of claim 27, wherein the promoter is selected from the vaccinia virus 7.5-kD promoter (P7.5k), 11-kD promoter (P11k), or 28-kD promoter (P28k), an artificial synthetic Poxvirus promoter (Ps), the chicken beta-actin (Bac) promoter or a derivative thereof, the Pec promoter, the Murine Cytomegalovirus (Mcmv) immediate-early (ie)1 promoter, the Human Cytomegalovirus promoter (Hcmv), the Simian virus (SV)40 promoter, and the Raus Sarcoma virus (RSV) promoter, or fragments thereof which retain a promoter activity.

### Claim 29 (depends on 19)

The rSPV of claim 19, which comprises an inactive serpin gene and which further comprises a nucleic acid sequence encoding a PCV antigen inserted into the IL18bp gene of the rSPV genome.

### Claim 30 (depends on 19)

A nucleic acid molecule comprising the genome of a rSPV of claim 19.

### Claim 31 (depends on 19)

A host cell comprising a rSPV of claim 19 or a nucleic acid molecule encoding the genome of said rSPV.

### Claim 32 (depends on 30)

A method for producing a rSVP comprising infecting a competent cell with a nucleic acid molecule of claim 30 and collecting the rSVP.

### Claim 33 (depends on 19)

A composition comprising a rSVP of claim 19 and an excipient.

### Claim 34 (depends on 33)

The composition of claim 33, said composition comprising a vaccine composition.

### Claim 35 (depends on 19)

A method of immunizing a porcine comprising administering a rSPV of claim 19 to said porcine.

### Claim 36 (depends on 34)

A vaccination kit for immunizing a porcine which comprises the following components:
a) an effective amount of a vaccine composition of claim 34, and
b) a means for administering said vaccine to said porcine.
